Making the discoveries that defeat cancer

  • Home »
  • Research »
  • Repository

  • Administrators Login

  • Repository Homepage
  • About the Repository
  • Browse the Repository
  • Search the Repository
  • Contribute an Article
  • Missing Publications
  • Repository Help

Inhibitors of the HSP90 molecular chaperone: Attacking the master regulator in cancer

Tools
- Tools
+ Tools

McDonald, E., Workman, P., Jones, K. (2006) Inhibitors of the HSP90 molecular chaperone: Attacking the master regulator in cancer. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 6 (11). pp. 1091-1107. ISSN 1568-0266

Full text not available from this repository.

Abstract

Inhibitors of the HSP90 molecular chaperone: Attacking the master regulator in cancer The heat shock protein 90 (HSP90) chaperones represent some 1-2% of all cellular protein and are key players in protein quality control in cells. They are over expressed in many human cancers and the fact that many oncogenic proteins are clients has prompted much recent research on HSP90 inhibitors as new cancer therapeutics. A brief introduction is followed by a detailed review of the various classes of inhibitors, both natural product-based and synthetic, that have emerged over the last decade. The natural products geldanamycin, radicicol and novobiocin have provided the start points for new drugs in this area and their medicinal chemistry is reviewed, including the exciting recent results emerging from clinical trials using geldanamycin analogues. The detailed understanding of the binding mode of these compounds to HSP90 has been significantly enhanced by X-ray crystallography of HSP90 constructs co-crystallised with various ligands. Efforts to replace the natural product inhibitors with more drug-like synthetic compounds have mushroomed over the last 4 years. The purines and the 3,4-diarylpyrazoles have proven to be the most successful and their medicinal chemistry is reviewed with particular emphasis on structure-based design. Protein/ligand co-crystal structures have shown that conserved water molecules in the active site are a vital part of the hydrogen-bonding network established on binding both natural product and synthetic inhibitors. Medicinal chemists have used this information to develop high affinity lead compounds. Recent research provides the platform for exciting developments in the area of HSP90 inhibition over the next few years.

Item Type: Review Article
Authors (ICR Faculty only): Workman, Paul and McDonald, Ted and Jones, Keith
All Authors: McDonald, E., Workman, P., Jones, K.
Uncontrolled Keywords: Heat-shock response; structure-based design; in-vivo; biological evaluation; atp-binding; geldanamycin analogs; selective depletion; efficient synthesis; novobiocin analogs; antitumor-activity
Research teams: ICR divisions > Cancer Therapeutics > Clinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group)
ICR divisions > Cancer Therapeutics > Medicinal Chemistry 3
ICR divisions > Cancer Therapeutics > Signal Transduction & Molecular Pharmacology
Date Deposited: 10 Aug 2007 21:06
Last Modified: 21 Apr 2010 10:20
URI: http://publications.icr.ac.uk/id/eprint/3884

Actions (login required)

View Item View Item
The Royal Marsden - NHS foundation trust